DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the UNICHEM LABORATORIES LTD (UNICHEMLAB) share price today?

UNICHEM LABORATORIES LTD (UNICHEMLAB) is trading at ₹589.05 on the NSE, down 2.61% on the day. Source: DocStoX.

What is the PE ratio of UNICHEM LABORATORIES LTD?

UNICHEM LABORATORIES LTD has a price-to-earnings (PE) ratio of 16.4 in the Healthcare sector.

What is the market capitalisation of UNICHEM LABORATORIES LTD?

UNICHEM LABORATORIES LTD has a market capitalisation of approximately ₹4,150 crore.

UNICHEM LABORATORIES LTD

UNICHEMLAB·NSE·Healthcare

₹589.05▼ -15.80 (-2.61%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹571.95

₹603.20

52W₹278

₹68776%

Open

₹598.10

High

₹603.20

Low

₹571.95

Prev Close

₹604.85

Volume

1.58L

VWAP

₹588.34

Snapshot

Key fundamentals

Market Cap

₹4,150 Cr

P/E Ratio

16.40Fair

P/B Ratio

1.21

EPS

₹35.91

Book Value

₹386.00

ROE

3.03%Weak

ROCE

4.00%Weak

Dividend Yield

0.61%

Debt / Equity

0.18Low

Face Value

₹2.00

52W High

₹687.20

52W Low

₹278.20

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatHigh uncertainty

Fair value estimate

₹391

▼ 33.7%downside

Trading at ₹589 — 34% above our estimate

BearFair valueBull

₹332₹391₹558

/100

Business quality — Solid

Growth 72Profitability 26Efficiency 0Valuation 88

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (3%)

Strengths

Low debt relative to equity
Revenue compounding 18% over 3 years
Promoters hold a controlling stake

Risks

Weak returns on equity (3%)
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

3% ROE fading to 12% over ~3 yrs, on ₹386 book

₹344

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹558

Analyst target

No analyst coverage

—

Blended fair value₹391

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 18% over 3 years
Promoters hold a controlling stake

Bear case

Weak returns on equity (3%)
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

16.4Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

3.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

4.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.18Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹4,150 Cr

P/B

1.21

EPS

₹35.91

Div Yield

0.61%

What changed

Recent changes

Domestic institutions-0.1% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 16.4×

Growth

Strong

+18% rev CAGR

Profitability

Modest

3.0% ROE

Financial health

Rock solid

D/E 0.18

Momentum

N/A

No technicals

Today

Trading activity

Delivery %31.4%

Turnover₹931.72L Cr

Trades7,548

VWAP₹588.34

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+17.9%

+12.3%

10Y

+5.2%

Profit

—

+49.4%

10Y

+8.9%

EPS

—

+49.1%

10Y

+11.7%

Profile

Pros

Company has delivered good profit growth of 25.0% CAGR over last 5 years

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 2.34% over last 3 years.
Earnings include an other income of Rs.260 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Domestic institutions reduced 0.11 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

70%

Promoter

Promoters

70.2%0.00

Public

15.2%+0.04

FII / FPI

1.0%+0.01

DII

10.6%-0.11

Others

2.9%

Total shareholders

23,386+119 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter70.22%

FII1.00%

DII10.63%

Public15.22%

Others2.93%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas.[1]